Free tool
FAERS Monitor: Lipiodol
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 009190 or its brand name (Lipiodol, Ethiodized Oil). Reports on generic versions are filed under their own applications.
Reports
1,298
Serious
1,258
97% of reports
Hospitalization
286
Death reported
154
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product use in unapproved indication294
- off label use170
- liver abscess73
- pyrexia59
- pulmonary embolism49
- product use issue43
- aspartate aminotransferase increased40
- pancytopenia36
- alanine aminotransferase increased35
- disease progression33
- overdose31
- hepatic artery stenosis30
- cerebral artery embolism28
- maternal exposure before pregnancy28
- hypothyroidism27
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2006 | 6 |
| 2007 | 3 |
| 2008 | 3 |
| 2009 | 8 |
| 2010 | 7 |
| 2011 | 29 |
| 2012 | 26 |
| 2013 | 25 |
| 2014 | 25 |
| 2015 | 64 |
| 2016 | 82 |
| 2017 | 109 |
| 2018 | 123 |
| 2019 | 97 |
| 2020 | 76 |
| 2021 | 64 |
| 2022 | 67 |
| 2023 | 86 |
| 2024 | 144 |
| 2025 | 109 |
| 2026 | 143 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,861 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hepatic artery stenosisSignal | 30 | 4865.8 | 3247.5 | 108,532 |
| cerebral artery embolismSignal | 28 | 381.3 | 263.2 | 10,009 |
| liver abscessSignal | 73 | 373.0 | 297.7 | 26,119 |
| maternal exposure before pregnancySignal | 28 | 66.7 | 46.2 | 1,740 |
| product use in unapproved indicationSignal | 294 | 19.2 | 17.4 | 5,121 |
| hypothyroidismSignal | 27 | 13.7 | 9.4 | 306 |
| aspartate aminotransferase increasedSignal | 40 | 12.2 | 9.0 | 401 |
| pancytopeniaSignal | 36 | 10.4 | 7.6 | 299 |
| alanine aminotransferase increasedSignal | 35 | 9.2 | 6.7 | 250 |
| pulmonary embolismSignal | 49 | 8.4 | 6.4 | 311 |
| disease progressionSignal | 33 | 4.5 | 3.2 | 87 |
| product use issueSignal | 43 | 3.7 | 2.8 | 83 |
| off label useSignal | 170 | 3.1 | 2.7 | 257 |
| pyrexiaSignal | 59 | 2.8 | 2.2 | 66 |
| overdoseSignal | 31 | 2.3 | 1.6 | 22 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.